New Non-toxic Compounds that Sensitize Cells for DNA Damage Agents and Serving as Adjuvants in Chemotherapy of Cancer

University of California System: University of California, Irvine
posted on 06/16/2009

BRCA2/RAD5 1 interaction is essential for DNA repair mechanisms and play significant role in tumor resistance to irradiation and chemotherapy treatments. Effective strategies to selectively interfere with BRCA2/RAD5 1 interaction in the context of treatment and chemoprevention of neoplastic diseases are described.

Suggested Uses

Adjutants in chemotherapy of cancer, specifically tested in CML and Leukemia.

Innovation Details

Detailed Description

The present invention is directed to compositions and methods in which a compound interferes, and most typically disrupts or prevents BRCA2/RAD5 1 interaction, and / or RAD5 1 multimerization. Two small compounds with molecular weight about 300-400 were isolated from reverse yeast two hybrid screening using a chemical library containing 30000 compounds. These compounds disrupt the interaction between BRCA2 and Rad51 and lead to sensitive to DNA damage agents such as ionizing radiation or cisplatinim treatment. Therefore, these compounds can be used as drugs for sensitizing cancer cells for chemotherapy.

The inhibitors were tested successfully in CML cell lines, including Imatinib-resistant cell lines. Imatinib is a standard CML treatment; however its activity is limited by frequently developed tumor resistance. The inhibitors successfully reduced or eliminated human breast cancer transplanted into nude mice. Further, the inhibitors were active in mouse model of CML (Bcr-Abl mice). Currently inventors are analyzing combinational treatment of inhibitors with Imatinib to eliminate or delay Imatinib resistance in mice.

File Number: 18782 

Disease: Autoimmune and Inflammation

IP Protection

Patent Number(s): 2009/0312324
Copyright: ©2009-2010, The Regents of the University of California

License Online

This innovation currently is not available for online licensing. Please contact Maria Tkachuk at University of California System: University of California, Irvine for more information.

Request more info via email request more info

Case Manager:

Maria  Tkachuk Maria Tkachuk

Innovations (30)

Download Technology Brief (PDF)

Followed By

Follow this innovation

No one is following this innovation.

Related Tags

Find more innovations

February 11, 2009

13,565 members 17,723 innovations 176 organizations


Martin Lehr, Osage University Partners

"iBridge is a great resource for entrepreneurs who are looking for technologies to license. Many premiere universities including Michigan, Columbia, MIT, Penn, and Harvard, participate in the iBridge program."  read more...